Cullen Capital Management LLC reduced its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,100,496 shares of the company's stock after selling 185,517 shares during the period. Kenvue accounts for approximately 2.2% of Cullen Capital Management LLC's portfolio, making the stock its 19th biggest holding. Cullen Capital Management LLC owned 0.47% of Kenvue worth $194,296,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in KVUE. Grove Bank & Trust raised its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the fourth quarter valued at $29,000. SRS Capital Advisors Inc. boosted its holdings in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its holdings in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after purchasing an additional 1,441 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the company. Redburn Atlantic assumed coverage on Kenvue in a research note on Thursday. They issued a "neutral" rating and a $23.50 price target on the stock. Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Evercore ISI assumed coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective on the stock. Finally, Barclays increased their target price on Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $23.96.
Get Our Latest Analysis on Kenvue
Kenvue Stock Down 0.5 %
NYSE KVUE traded down $0.12 during trading hours on Thursday, hitting $21.66. 7,873,562 shares of the company traded hands, compared to its average volume of 16,882,102. The stock has a market capitalization of $41.40 billion, a price-to-earnings ratio of 40.87, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The business's 50-day moving average is $22.61 and its 200-day moving average is $22.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.79%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is currently 154.72%.
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
